Eli Lilly and Company $LLY Shares Sold by South Dakota Investment Council

South Dakota Investment Council reduced its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 62,814 shares of the company’s stock after selling 557 shares during the quarter. Eli Lilly and Company accounts for 0.9% of South Dakota Investment Council’s investment portfolio, making the stock its 12th largest position. South Dakota Investment Council’s holdings in Eli Lilly and Company were worth $48,965,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in LLY. State of Michigan Retirement System raised its position in Eli Lilly and Company by 0.6% in the second quarter. State of Michigan Retirement System now owns 265,504 shares of the company’s stock valued at $206,968,000 after purchasing an additional 1,700 shares during the period. Carson Advisory Inc. grew its stake in shares of Eli Lilly and Company by 4.0% in the second quarter. Carson Advisory Inc. now owns 647 shares of the company’s stock valued at $504,000 after buying an additional 25 shares in the last quarter. Nicholas Company Inc. raised its holdings in shares of Eli Lilly and Company by 9.4% in the 2nd quarter. Nicholas Company Inc. now owns 92,014 shares of the company’s stock valued at $71,728,000 after buying an additional 7,940 shares during the period. Tredje AP fonden lifted its stake in Eli Lilly and Company by 18.8% during the 2nd quarter. Tredje AP fonden now owns 304,733 shares of the company’s stock worth $237,549,000 after acquiring an additional 48,160 shares in the last quarter. Finally, Eleva Capital SAS acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $1,287,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Leerink Partners restated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $940.00.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $862.96 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The stock has a market cap of $816.76 billion, a P/E ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a 50-day simple moving average of $780.74 and a 200-day simple moving average of $771.71.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.